^
    Back
    Association details:
    Biomarker:ALK R1275Q
    Cancer:Neuroblastoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Nat Commun
    Title:

    Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

    Published date:
    05/05/2023
    Excerpt:
    Patient 3 harbored a germline ALK R1275Q mutation that remained stable at the expected 50% VAF, with complete response to lorlatinib….These data allow the elucidation of mechanisms of response and resistance to ALK inhibition with lorlatinib in patients with relapsed/refractory ALK-mutated neuroblastoma...
    DOI:
    https://doi.org/10.1038/s41467-023-38195-0